Peptide improved movement in mouse models of brain disease
Daily injections from 3 to 12 months of age improved movement and behavior in male and female mice modeling Huntington’s disease.
Our read
Interventions- Studied:
- Experiments in animals
Editor of record: Boris Djordjevic · AgingResearch.News
Male and female zQ175 mice, a model of Huntington’s disease, received TT-P34 in an animal experiment. Researchers injected the peptide, a short chain of amino acids, under the skin daily at 0.2 milligrams per kilogram of body weight from 3 to 12 months of age. Compared with mice given injections without the peptide, they showed improved movement and behavior. TT-P34 also preserved molecular patterns associated with nerve-cell connections and mitochondria, the cells’ energy-producing structures, in a brain region called the striatum.
In another animal experiment, mice exposed to MPTP, a toxin used to model Parkinson’s disease, received daily TT-P34 injections at five doses ranging from 0.0016 to 1 milligram per kilogram. The peptide eased movement problems and preserved dopamine-producing nerve cells.
Why it matters
Mitochondrial dysfunction is a hallmark of neurodegeneration. The authors propose targeting SorCS2, a receptor involved in nerve-cell support, as a strategy to prevent neurodegeneration.
Caveats
The benefits came from mouse disease models, not tests in people. In the Parkinson’s model, dosing began one day before toxin exposure.
The paper
The SorCS2-derived macrocycle TT-P34 drives neuroprotection in animal models of neurodegeneration
Aarhus University
Acta Neuropathologica Communications, Aug 10, 2026, Open access
Comments
Be the first to comment.